FDA APPROVES EXPANDED USE OF $BSX (BOSTON SCIENTIFIC) DEVICES
Typically we refrain from posting on this blog the information that is easily available elsewhere. In view of us taking long position on BSX immediately after seven broker downgrades and the importance of this FDA decision, we are making an exception. Here is the reason for Boston Scientific going up after hours.
Today Circulatory System Devices Panel of the U.S. Food and Drug Administration (FDA) has unanimously recommended approval of an expanded indication for its cardiac resynchronization therapy defibrillators (CRT-Ds), including the COGNIS ® CRT-D. The panel recommended the expansion include the majority of the studied population of the landmark MADIT-CRT clinical trial, which evaluated the ability of these devices to slow the progression of heart failure in patients with asymptomatic or mild heart failure.… Please click here or the title below to read more.